Alex Thompson
Stock Analyst at Stifel
(3.90)
# 647
Out of 5,124 analysts
41
Total ratings
63.64%
Success rate
8.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $209.29 | +22.32% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $803.74 | +55.27% | 5 | Dec 11, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $80 → $56 | $43.91 | +27.53% | 2 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $36.20 | +79.56% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $35.80 | -30.17% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $10.16 | +116.54% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $73.46 | -25.13% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $15.91 | +126.34% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $45.95 | +30.58% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $26.62 | +84.07% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $30.33 | +78.04% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $10.05 | -80.10% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $11.17 | +517.73% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $2.65 | -62.26% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $30.72 | +30.21% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $30.83 | +937.95% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $25.90 | +31.27% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.28 | +2,478.13% | 1 | Dec 14, 2022 |
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $209.29
Upside: +22.32%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $803.74
Upside: +55.27%
AnaptysBio
Dec 11, 2025
Maintains: Buy
Price Target: $80 → $56
Current: $43.91
Upside: +27.53%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $36.20
Upside: +79.56%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $35.80
Upside: -30.17%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $10.16
Upside: +116.54%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $73.46
Upside: -25.13%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $15.91
Upside: +126.34%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $45.95
Upside: +30.58%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $26.62
Upside: +84.07%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $30.33
Upside: +78.04%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $10.05
Upside: -80.10%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $11.17
Upside: +517.73%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $2.65
Upside: -62.26%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $30.72
Upside: +30.21%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $30.83
Upside: +937.95%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $25.90
Upside: +31.27%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.28
Upside: +2,478.13%